Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01053858

Enrollment

Registered

2010-01-22

Start date

2008-01-31

Completion date

2010-01-31

Last updated

2010-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity

Keywords

bevacizumab,triamcinolone, intravitreal injection

Brief summary

To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.

Interventions

PROCEDUREintravitreal injection

intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion

Exclusion criteria

* previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset * Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders * neovascularization on the disc or elsewhere or rubeosis

Design outcomes

Primary

Measure	Time frame
best corrected visual acuity	baseline, 1 month, 2 months, 3 months, 6 months, 12 months

Secondary

Measure	Time frame
central macular thickness by optical coherence tomography	baseline, 1 month, 2 months, 3 months, 6 months 12months

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026